VI
OCUL icon

Versor Investments’s Ocular Therapeutix OCUL Stock Holding History

Versor Investments’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-33,400
Closed -$134K – 902
2022
Q2 		$134K Buy
33,400
+19,300
+137% +$72.9K 0.01% 768
2022
Q1 		$70K Sell
14,100
-15,400
-52% -$85.4K ﹤0.01% 601
2021
Q4 		$206K Buy
29,500
+19,200
+186% +$149K 0.01% 501
2021
Q3 		$103K Buy
+10,300
New +$116K ﹤0.01% 496

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Versor Investments's OCUL Position: Q3 2022 in Review

Versor Investments sold out of Ocular Therapeutix (OCUL) in Q3 2022, closing a stake of 33,400 shares — an estimated $134K sold.

Versor Investments first reported a position in OCUL in Q3 2021 and held it in 4 quarters. The position peaked at $206K in Q4 2021. 130 funds tracked by Wall St. Rank hold OCUL as of Q3 2022.

  • Versor Investments reported no remaining Ocular Therapeutix position as of Q3 2022 after selling out during the quarter.
  • Versor Investments sold 33,400 Ocular Therapeutix shares in Q3 2022, an estimated $134K.
  • Versor Investments first reported a position in Ocular Therapeutix in Q3 2021 and held it in 4 quarters.
  • Versor Investments's Ocular Therapeutix position peaked at $206K in Q4 2021.
  • 130 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2022.

Based on Versor Investments's 13F filing for Q3 2022, filed 25 Oct 2022.